This single-center, open-label, two-arm interventional study aims to evaluate the efficacy and safety of a probiotic-uricase complex preparation in patients with hyperuricemia. Participants aged 18 to 60 years with hyperuricemia will be assigned to either the intervention group or the control group. Participants in the intervention group will receive the probiotic-uricase complex preparation during a 2-week treatment period according to the study protocol in addition to conventional management, while participants in the control group will receive conventional management alone. Blood, urine, and fecal samples will be collected at baseline and during follow-up. The primary goal is to assess the change in serum uric acid from baseline after treatment. Secondary assessments include changes in uric acid-related metabolites in blood, urine, and feces, alterations in gut microbiota composition based on metagenomic analysis, and safety outcomes including laboratory parameters and adverse events. This study will explore whether the probiotic-uricase complex may serve as a safe and effective oral intervention for improving uric acid metabolism in patients with hyperuricemia.
Age 18-60 years.
Men with serum uric acid levels > 420 μmol/L on 2 separate occasions (not on the same day), women with serum uric acid levels > 360 μmol/L on 2 separate occasions (not on the same day).
Participants must sign an informed consent form and be able to cooperate with sample collection.
A history of or current presence of a clearly defined organic intestinal disease, such as intestinal malignant tumor, inflammatory bowel disease, intestinal obstruction, or intestinal polyp.
Concurrent severe systemic diseases, including severe cardiovascular or cerebrovascular disease (eg., myocardial infarction within the past 6 months, NYHA Class III-IV heart failure, or uncontrolled hypertension), significant liver function abnormalities (ALT or AST > 2 times the upper limit of normal), moderate-to-severe renal insufficiency (eGFR < 45 mL/min/1.73 m²) or uncontrolled diabetes (HbA1c ≥ 9%).
Use of antibiotic, probiotic preparation, or other drugs that may significantly alter the gut microbiota within 4 weeks prior to enrollment, or those requiring continued use of such drugs during the study.
Women who are pregnant or lactating, or who plan to become pregnant during the study.
Parallel
Probiotic-uricase complex preparation
Dietary supplementParticipants receive the probiotic-uricase complex preparation capsule orally. Each participant takes it for 2 weeks. Adherence is monitored through capsule counts and diaries. Clinical and biological evaluations will include blood, urine, and fecal sample collection for assessment of uric acid metabolism, related metabolites, gut microbiota composition, and safety parameters. Serum uric acid will be monitored longitudinally to evaluate changes from baseline during treatment and post-treatment follow-up.
Change in serum uric acid from baseline
Change in serum uric acid from baseline to Weeks 1, 2, 3, and 4.
Change in uric acid-related metabolites in blood, urine, and feces
Changes in uric acid-related metabolites, including uric acid and allantoin, in blood, urine, and fecal samples.
Change in gut microbiota composition based on fecal metagenomic analysis
Changes in gut microbiota composition and relative abundance of uric acid metabolism-related microorganisms based on fecal metagenomic analysis.
Change in uric acid metabolism-related microbial functional genes
Changes in the abundance of microbial functional genes related to uric acid metabolism, including genes identified through fecal metagenomic analysis.
Safety and tolerability: Incidence of treatment-emergent Adverse Events (AEs)
Treatment-emergent adverse events will be monitored throughout the 4-week intervention period. Results will be reported as the number and percentage of participants experiencing adverse events (AEs) after initiation of the probiotic intervention.
Click on the lead sponsor to view all of their trials.
Maanshan Shiqiye Hospital
Lead sponsor
Institute of Process Engineering, Chinese Academy of Sciences
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
